Barrier device for ostium of left atrial appendage

Information

  • Patent Grant
  • 6551303
  • Patent Number
    6,551,303
  • Date Filed
    Wednesday, October 27, 1999
    25 years ago
  • Date Issued
    Tuesday, April 22, 2003
    21 years ago
Abstract
A membrane applied to the ostium of an atrial appendage for blocking blood from entering the atrial appendage which can form blood clots therein is disclosed. The membrane also prevents blood clots in the atrial appendage from escaping therefrom and entering the blood stream which can result in a blocked blood vessel, leading to strokes and heart attacks. The membranes are percutaneously installed in patients experiencing atrial fibrillations and other heart conditions where thrombosis may form in the atrial appendages. A variety of means for securing the membranes in place are disclosed. The membranes may be held in place over the ostium of the atrial appendage or fill the inside of the atrial appendage. The means for holding the membranes in place over the ostium of the atrial appendages include prongs, stents, anchors with tethers or springs, disks with tethers or springs, umbrellas, spiral springs filling the atrial appendages, and adhesives. After the membrane is in place a filler substance may be added inside the atrial appendage to reduce the volume, help seal the membrane against the ostium or clot the blood in the atrial appendage. The membranes may have anticoagulants to help prevent thrombosis. The membranes be porous such that endothelial cells cover the membrane presenting a living membrane wall to prevent thrombosis. The membranes may have means to center the membranes over the ostium. Sensors may be attached to the membrane to provide information about the patient.
Description




BACKGROUND OF THE INVENTION




1. Field of the Invention




The invention relates to a membrane or plug structure applied to the ostium of an atrial appendage for preventing blood flow and physical connection between an atrium of the heart and the associated atrial appendage or appendages to isolate an atrial appendage and prevent thrombus leaving therefrom.




2. Description of the Related Art




There are a number of heart diseases (e.g. coronary artery disease, mitral valve disease) that have various adverse effects on the heart. An adverse effect of certain cardiac diseases, such as mitral valve disease, is atrial (or auricular) fibrillation. Atrial fibrillation may result in pooling of blood in the left atrial appendage. Blood pooling may also be spontaneous. When blood pools in the atrial appendage, blood clots can form and accumulate therein, build upon themselves, and propagate out from the atrial appendage into the atrium. These blood clots can then enter the systemic or pulmonary circulations and cause serious problems if they migrate from the atrial appendage and become free in the blood stream and embolize distally into the arterial system. Similar problems also occur when a blood clot extending from an atrial appendage into an atrium breaks off and enters the blood supply. Since blood from the left atrium and ventricle supply the heart and brain, blood clots from the atrial appendages can obstruct blood flow therein causing heart attacks, strokes or other organ ischemia. It is therefore necessary to find a means of preventing blood clots from forming in the atrial appendages and to prevent these blood clots, once formed, from leaving the atrial appendages to the heart lungs, brain or other circulations of the patient which can cause heart attacks or strokes or other organ ischemia




U.S. Pat. No. 5,865,791 relates to the reduction of regions of blood stasis and ultimately thrombus formation in such regions, particularly in the atrial appendages of patients with atrial fibrillation. More specifically, the invention relates to procedures and devices for affixing the atrial appendages in an orientation that prevents subsequent formation of thrombus. The invention removes the appendage from the atrium by pulling on it and putting a loop around it to form a sack of the atrial appendage and then cut off from the rest of the heart.




U.S. Pat. No. 5,306,234 relates to a method for surgically closing the passage between the atrium and the atrial appendage or severing the atrial appendage.




Other methods of treatment include surgically removing the atrial appendages to prevent blood stasis in the atrial appendages.




SUMMARY OF THE INVENTION




The invention provides a membrane or plug structure for preventing blood from entering the atrial appendages to form blood clots and prevents blood clots formed in the atrial appendages from exiting therefrom which may cause heart attacks, strokes and other embolic events. The membrane covers the ostium of the atrial appendage and effectively isolates it from the atrium. It may be larger than the ostium of the appendage, and extend over an area larger than the appendage ostium. It is percutaneously delivered to the ostium of the atrial appendage by a catheter and then expanded to cover the ostium and has a means to attach the membrane over the ostium. The membrane itself may be porous or non-porous. In the case of a porous membrane, it can become infiltrated with cells so that it becomes a “living” structure, and can develop an endothelial/endocardial lining to enable it in turn to become a non-thrombogenic surface. There are many means for fixing the membrane to cover the ostium of the atrial membrane. The membrane's attachment devices have a means for self-centering the membrane over the appendage ostium. The membrane may be glued on, or have a stents or prongs which pass through the ostium and extend into or through the atrial appendage. Alternatively an anchor in the wall of the atrial appendage may be tethered to the membrane for holding the membrane in place. Springs may also extend between the anchor and the membrane to hold the membrane against the ostium. The membrane may also be connected to a tether, elastic tether or spring and placed through the atrial appendage wall for holding the membrane against the ostium and may pull on the atrial appendage such that its volume is reduced or eliminated, trapping and isolating blood clots therein. Thrombin, activated fibrinogen, or other biologic filler may be placed in the appendage after it has been sealed, with the express purpose of clotting the blood in the appendage, yet preventing clots from escaping the appendage.




Part of the device may involve a suction apparatus to remove clots that are already in place. The membrane placement may require closure of an atrial septal defect created by the placement of this appendage occluder device.




Alternatively the membrane may be held in place by a coiled spring filling the volume of the atrial appendage. The membrane may also fill the atrial appendage itself preventing blood from entering or blood clots from leaving.




The membrane itself may be porous or non-porous. In the case of a porous membrane, it can become infiltrated with cells so that it becomes a “living” structure, and can develop an endothelial/endocardial lining to enable it in turn to become a nonthrombogenic surface. It thus can develop an endothelium and with time becomes highly biocompatible. It may be heparin-coated to prevent thrombus from forming on the membrane surface, immediately after placement and until it infiltrates with cells and/or develops an endothelial covering.




The device, when implanted in the atrial appendage, may also have the ability to perform electrical monitoring of the heart. This would consist of two or more electrical contacts placed apart on the device, and connected to signal conditioning circuitry for determination of cardiac features such as rhythm of the atria or ventricles. Another sensor on the device could measure pressure of the atria, atrial appendage, or ventricular end diastolic pressures (left or right) through the open mitral or tricuspid valves. A suitable telemetry system would be used to telemeter this important electrical and hemodynamic information non-invasively outside the patient. Also, memory could be present on the device in order to record the information for later recovery via noninvasive telemetry.




This device can also be used to close filstulae or connections elsewhere in the body, such as in the colon or bronchopulmonary systems. Another application of the device would be to seal and strengthen false aneuryms of the left ventricle by holding the membrane against the false aneurysm. The same principles apply, whereby the membrane is held against the fistulae or false aneurysm, held in place by the spring or prong mechanisms.




The device can also be used to chemically ablate the myocardial tissue of the atrial appendage in order to help limit or eliminate the electrical propagation of atrial fibrillation.




OBJECTS OF THE INVENTION




It is an object of the invention to reduce the volume of an atrial appendage to reduce the size of the region for potential blood stasis formation, and consequently the effective volume of the affected atrium.




It is an object of the invention to measure hemodynamics pressure (or flow), or electrical signals in the heart and telemeter them outside the body for diagnosis or monitoring.




It is an object of the invention to be able to close fistulae or connections elsewhere in the body, such as in the colon or bronchopulmonary systems.




It is another object of the invention for the membrane to be placed in a false aneurysm to strengthen this defect, and to avoid surgery.




It is an object of the invention to reduce the region of static blood in the atrial appendages and hence the thrombogenicity of the atrium.




It is an object of the invention to prevent blood clots from forming in the atrial appendages.




It is an object of the invention to replace the ostium of the atrial appendage with a non-thrombogenic, biocompatible surface that prevents blood clots from forming.




It is an object of the invention to provide a porous membrane surface which becomes lined with endothelial or endocardial cells.




It is an object of the invention to isolate the atrial appendage from the atrium proper and prevent communication through which thrombus could migrate.




It is an object of the invention to minimally invasively prevent blood clots from forming in the atrial appendages and escaping therefrom.




It is an object of the invention to provide a filter between the atrium and atrial appendage to prevent blood clots from flowing therebetween.




It is an object of the invention to fill the atrial appendage with a material to prevent blood clots from leaving the atrial appendage.




It is an object of the invention to remove thrombi from the atrium via suction or other means.




It is an object of the invention to provide a means for securing a membrane over the ostium of the atrial appendage that is colonized with cells and provide a highly biocompatible surface including but not limited to endothelialization.




It is an object of the invention to prevent thrombus by use of heparin or other anti-thrombogenic substance on or eluted from the membrane.




It is an object of the invention to seal the membrane with a substance injected into the atrial appendage.




It is an object of the invention to clot the blood inside of the atrial appendage after the membrane is in place with a substance injected into the atrial appendage.




It is an object of the invention to inject a substance into the sealed appendage to ablate the myocardial cells of the appendage, in order to limit the propagation of atrial fibrillation.




It is an object of the invention to ensure the membrane is centered over the ostium of the atrial appendage.




It is an object of the invention to accurately place the membrane over the ostium of the atrial appendage.




Other objects, advantages and novel features of the present invention will become apparent from the following detailed description of the invention when considered in conjunction with the accompanying drawings.











BRIEF DESCRIPTION OF THE DRAWINGS





FIG. 1

is a partial cross sectional view of a heart showing a catheter entering the left atrial appendage using a retrograde procedure from the aorta.





FIG. 2

is a partial cross sectional view of a heart showing a catheter entering the left atrial appendage using a transeptal procedure from the femoral vein or superior vena cava.





FIG. 3

is a partial cross sectional view of a heart showing a catheter entering the right atrial appendage from the jugular vein or optionally from the femoral vein.





FIG. 4

is a partial cross sectional view of a portion of a heart showing an atrium and its associated atrial appendage.





FIG. 5

is a partial cross sectional view of a portion of a heart showing an atrium and its associated atrial appendage with a porous membrane having flexible wire prongs with atraumatic bulbs to hold the membrane in place and electronics built into the membrane.





FIG. 6

is similar to

FIG. 5

with the atraumatic bulbs removed so that the flexible wire prongs may puncture the atrium wall and secure the membrane to the atrial appendage and a centering rim added to the membrane.





FIG. 7

is a partial cross sectional view of a portion of a heart as in

FIG. 5

with a stent portion between the membrane and the prongs.





FIG. 8

is the same as

FIG. 7

with the atraumatic bulbs removed so that the flexible wire prongs may puncture the atrium wall and secure the membrane to the atrial appendage.





FIG. 9

is a partial cross sectional view of a portion of a heart showing an atrium and its associated atrial appendage with a porous membrane having a large expandable stent to hold the membrane in place.





FIG. 10

is a partial cross sectional view of a portion of a heart showing an atrium and its associated atrial appendage having an anchor and a tether to hold the membrane in place.





FIG. 11

is a partial cross sectional view of a portion of a heart showing an atrium and its associated atrial appendage having an anchor and a spring to hold the membrane in place, a centering rim on the membrane and a centering cable.





FIG. 12

is the same as

FIG. 11

with the spring filling the atrium to help hold the membrane in place.





FIG. 13

is a partial cross sectional view of a portion of a heart showing an atrium and its associated atrial appendage with the membrane adhesively being held in place.





FIG. 14

is a partial cross sectional view of a delivery catheter having a disk, a spring and membrane therein.





FIG. 15

is a schematic view of a disk, spring and membrane after being expanded out of the delivery catheter of FIG.


11


.





FIG. 16

is a partial cross sectional view of a portion of a heart showing an atrium and its associated atrial appendage having a disk, a membrane and a spring therebetween.





FIG. 17

is a partial cross sectional view of a portion of a heart showing an atrium and its associated atrial appendage shown in a collapsed position.





FIG. 18

is a partial cross sectional view of a portion of a heart showing an atrium and its associated atrial appendage having a disk, a spring, a membrane and vacuum in the catheter.





FIG. 19

is a partial cross sectional view of a portion of a heart showing an atrium and its associated atrial appendage having a membrane material filling the atrial appendage.





FIG. 20

is a partial cross sectional view of a portion of a heart showing an atrium and its associated atrial appendage showing an umbrella folded for entering the atrial appendage.





FIG. 21

is a partial cross sectional view of a portion of a heart showing an atrium and its associated atrial appendage showing the umbrella opened in the atrial appendage to secure the umbrella into the wall of the atrial appendage.





FIG. 22

is a partial cross sectional view of a portion of a heart showing an atrium and its associated atrial appendage showing the umbrella and membrane sealing the ostium of the atrial appendage.





FIG. 23

is a partial cross sectional view of a portion of a heart showing an atrium and its associated atrial appendage showing a stent having a membrane for blocking the ostium of the atrial appendage.





FIG. 24

is a partial cross sectional view of a portion of a heart showing an atrium and its associated atrial appendage showing the atrial appendage reduced to a minimum volume by a disk and spring squeezing the appendage against a membrane.











DESCRIPTION OF THE PREFERRED EMBODIMENTS




Although atrial fibrillation results in pooling of blood in the left atrial appendage and the majority of use of the invention is anticipated to be for the left atrial appendage, the invention may also be used on the right atrial appendage and in general for any aperture in the body which needs to be blocked to prevent blood from flowing therethrough or therefrom.




As shown in

FIG. 4

a thrombus


30


may occur from pooling of blood in the left atrial appendage


13


due to poor circulation of blood therein when the patient experiences atrial fibrillation. To prevent thrombus


30


from forming in the left atrial appendage


13


or to prevent thrombosis formed therein from leaving and entering the blood stream which may cause a heart attack, a stroke or ischemia, a membrane


40


is placed across the ostium


20


of the atrial appendage


13


. The membrane


40


can be made of Teflon®, felt, Dacron®, silicone urethane, Gortex®, metal fibers or biocompatible polymers.




The membrane


40


may be a porous membrane. Porous membranes may consist of a biocompatible polymer which is porous, having pore sizes ranging from 20-100 microns. The pores may also be larger or smaller in rare cases. The membrane may also be a porous metal or a metal mesh of fine fibers which permit ingrowth of cells and covering with endothelial cells. The membrane may be coated with anticoagulant, or elute the anticoagulant.




The porous membrane colonizes with cells from the heart and so walls off the ostium


20


so that blood can not flow into the left atrial appendage


13


to form thrombus


30


and more importantly no thrombus


30


formed can leave the left atrial appendage


13


to cause heart attacks, strokes or ischemia.




The membrane


40


placed over the ostium


20


should be antithrombotic. In order to make the membrane antithrombotic, heparin or other anticoagulants or antiplatelet agent may be used on the membrane


40


.




When porous membranes


40


are used which have an ingrowth of cells, covering the membrane with endothelial cells, the endothelial cells present a smooth cellular wall covering the membrane which prevents thrombosis from occurring at the membrane.




When blood pools in the left atrial appendage


13


, thrombus


30


(blood clot) can accumulate therein, build upon themselves, and propagate out from the left atrial appendage


13


into the left atrium


11


entering the blood stream, leaving the heart and can block blood flow to the heart, brain, other organs, or peripheral vessels if it becomes lodged in the arteries thereof





FIGS. 1 and 2

show a cross section of a human heart showing a thrombus


30


in the left atrial appendage


13


. The figures also show the atrial appendage ostium


20


which is to have a membrane


40


placed over it to prevent the thrombus


30


from escaping out of the atrial appendage


13


into the left atrium


11


and thus into the blood stream, which could cause a stroke, a heart attack or ischemia. The membrane


40


also prevents blood from entering the left atrial appendage


13


where it could pool due to poor circulation and become a thrombus.





FIG. 3

shows a cross section of a human heart showing a thrombus


30


in the right atrial appendage


23


. The right atrial appendage


23


can be treated in the same manner as the left atrial appendage


13


.





FIG. 4

shows a cross section of the left atrium


11


, the ostium


20


and the left atrial appendage


13


having a thrombus


30


therein.





FIG. 5

shows a first embodiment of the invention wherein the porous membrane


40


has a plurality of flexible prongs


50


which may be made from a shape memory alloy, such as Nitinol®, for retaining a predisposed shape. The prongs


50


may be atraumatic so that they do not perforate the left atrial appendage


13


. The prongs


50


may have atraumatic bulbs


55


on their tips so that the tips of the prongs


50


will not perforate the left atrial appendage


13


. Nitinol® has the property of being able to be placed in a catheter in a compact configuration and then expanded when released from the catheter to a predetermined memory shape. The shape selected may be for the prongs


50


to curve around the lip of the ostium


20


and then hug the sides of the left atrial appendage


13


. In this manner the membrane


40


will securely block the ostium


20


preventing blood from entering and particularly for preventing thrombosis


30


from leaving the left atrial appendage


13


.




The membrane


40


is self centering over the ostium


20


of the left atrial appendage


13


, by placing the prongs


50


in a circle around the membrane


40


such that the prongs


50


fit against the wall of the left atrial appendage


13


of or within the lumen of the ostium


20


to center the membrane


40


over the ostium


20


. The membrane


40


may also be centered by a centering rim


65


(see

FIG. 6

) attached to the back (appendage) side of the membrane


40


that protrudes into the ostium


20


for centering. The centering rim


65


has a diameter of less than the diameter of the membrane


40


. The centering means may also consist of a series of centering cables


66


(see

FIG. 11

) which attach to a spring


90


or tether


85


from the centering rim


65


or the membrane


40


, to assure that centering occurs with placement




Optionally electronics, such as sensors


300


and chips


310


, built into the membrane may be used to provide data about hemodynamics pressure, flow rates, temperature, heart rates, and electrical signals in the heart. When the membrane is placed in the left atrial appendage


13


the sensors


300


may measure pressures in the atria or atrial appendage. The sensors may also measure ventricular end diastolic pressures through the open mitral or cuspid valves. Other information about the heart may be gathered such as noise from accelerometers to detect leakage, valve efficiency, activity levels of the patient and other noise related data. The sensors


300


may also be blood oxygen sensors. The chip


310


may use telemetry to transmit the information gathered by the sensors


300


and processed or stored by the chip


310


to receiving devices to aid in the treatment of the patient.




In

FIG. 6

the protective bulbs


55


are removed from the flexible prongs


50


of

FIG. 5

such that flexible prongs


50


puncture the walls of the left atrial appendage


13


and secure the membrane


40


in place. The flexible prongs


50


may penetrate into the atrial appendage wall or extend through the atrial appendage wall. The prongs may have barbed ends


51


to prevent the prongs from withdrawing from the atrial appendage wall.




The membrane


40


has centering rim


65


attached for centering the membrane in the ostium


20


and marker


320


in the membrane


40


for observing the position of the membrane while it is being inserted. The marker may be used for x-ray or ultrasound observation.




Although Nitinol® was cited above as a type of shape memory alloy prong material which can be used, any type of memory alloy may be used. Such alloys tend to have a temperature-induced phase change which will cause the material to have a preferred configuration when heated above a certain transition temperature. Other metals which may be used as prongs include corrosion resistant spring metals such as Elgiloy® or spring tempered steel.




Another embodiment of the invention is shown in FIG.


7


. It is similar to the embodiment shown in FIG.


5


. The embodiment in

FIG. 7

has a stent


60


attached to the membrane


40


for expanding in the ostium


20


helping to secure the membrane


40


thereto. The prongs


50


operate in the same manner as in

FIG. 5

hugging the inner walls of the left atrial membrane


13


to secure the membrane


40


to cover the ostium


20


. The stent


60


may also be made from Nitinol®, Elgiloy® or another expandable spring loaded or balloon expandable material.




The membrane


40


may be self centering over the ostium


20


of the left


13


atrial appendage, by placing the stent


60


into the ostium wherein the stent plugs the ostium with the membrane


40


centered in the stent. Further the prongs


50


fit against the wall of the left atrial appendage


13


of or within the lumen of the ostium


20


to center the membrane


40


over the ostium


20


.




In

FIG. 8

the protective bulbs


55


are removed from the flexible prongs


50


of

FIG. 7

such that flexible prongs


50


puncture the walls of the left atrial appendage


13


and secure the membrane


40


in place. The flexible prongs


50


may penetrate into the atrial appendage wall or extend through the atrial appendage wall. The prongs may have barbed ends


51


to prevent the prongs from withdrawing from the atrial appendage wall.




In the embodiment shown in

FIG. 9

a larger expandable stent


70


is used to both engage the sides of the ostium


20


and hug the inside walls of the left atrial membrane


13


. Again the stent may be made of Nitinol®, Elgiloy® or other material which may be delivered in a catheter and expanded to the proper size and shape to securely hold the membrane


40


over the ostium


20


to prevent blood from entering the left atrial appendage


13


and for preventing thrombosis


30


from exiting.





FIG. 10

shows another embodiment of the invention wherein the membrane


40


is secured over the ostium


20


by means of an anchor


80


which is driven into or through the wall of the left atrial appendage


13


and secured therein by the surface area of the anchor so that it will not pull out of or through the wall of the left atrial appendage


13


or cause embolism from the left atrial appendage


13


. A tether


85


is attached to the anchor


80


and to the membrane


40


to secure the membrane


40


snugly against the ostium


20


. A substance


270


such as thrombin, activated fibrinogen, or other biologic filler may be placed in the left atrial appendage


13


by injection through a catheter after the membrane


40


is in place such that blood is clotted in the atrial appendage so that it can not escape. The device delivery catheter itself may have a port for this injection. The port may also be used to inject contrast such as echocardiographic contrast that can be immediately visualized, and examined to determine whether there is a good seal between the ostium of the appendage and the device. The substance


270


injected into the atrial appendage may also be a sealant or filler to seal the membrane against leakage from the atrial appendage. The sealant material, filler material or blood clotting material may be used with any of the embodiments of the invention.




In another embodiment the catheter may inject a chemical ablation agent such as ethanol to ablate the myocardial cells in the sealed off atrial appendage


13


and thus limit atrial fibrillation by limiting or eliminating electrical propagation in the atrial appendage.





FIG. 11

shows another embodiment of the invention wherein membrane


40


has a spiral spring


90


in addition to the anchor


80


. The spiral spring


90


can be used in conjunction with or separately from the tether


85


to pull the membrane


40


against the ostium


20


. Although a spiral spring


90


has been shown in

FIG. 11

the shape used may be oval, cylindrical, oblong, or other shape to connect the anchor


80


to the membrane


40


. In another embodiment shown in

FIG. 12

the spiral spring


90


may fill the volume of the left atrial appendage


13


securing the membrane


40


to the ostium


20


. The spiral spring


90


filling the left atrial appendage


13


may also have an anchor


80


and tether


85


to help secure the membrane


40


to the ostium


20


. Alternatively centering rim


65


may be used as shown in

FIG. 11

to center the membrane


40


over ostium


20


of left atrial appendage


13


. Centering cables


66


connected to spring


90


and either membrane


40


or centering rim


65


may also be used to center the membrane


40


over the ostium


20


.





FIG. 13

shows yet another means of securing the membrane


40


over the ostium


20


. In this embodiment membrane


40


is directly attached to the ostium


20


by an adhesive


100


.





FIG. 14

shows a delivery catheter


125


containing a collapsed porous membrane


40


and a collapsed disk


130


connected to the porous membrane


40


by a spring


90


on catheter


21


. The disk


130


may be made of a flexible woven metal or a flexible woven metal with a thin porous polymer sandwiched inside. Disk


130


may also be a polymer weave. The disk


130


is flexible and compresses or folds so it fits into the delivery catheter


125


and expands to its desired shape after release from the delivery catheter


125


. Similarly membrane


40


compresses or folds to fit into the delivery catheter


125


and expands to its desired shape after release.

FIG. 15

shows the porous membrane


40


, disk


130


and spring


90


from

FIG. 14

in an expanded configuration outside of the delivery catheter


125


.





FIG. 15

shows the spring


90


connecting the porous membrane


40


and the disk


130


for urging them together. In other embodiments an elastic tether or a tether with teeth and a pawl on the porous membrane


40


to form a ratchet can also be used to pull the porous membrane


40


and the disk


130


together.





FIG. 16

shows the device of

FIG. 15

applied to the left atrial appendage


13


having thrombus


30


. After the device is applied the spring


90


, pulls the disk


130


toward the porous membrane


40


collapsing the left atrial appendage


13


and trapping the thrombus


30


therein as shown in FIG.


17


.





FIG. 18

shows an alternate embodiment of the device in

FIGS. 16 and 17

wherein the catheter


21


is equipped with a vacuum


140


for sucking out blood and thrombosis


30


found in the left atrial appendage


13


. The vacuum


140


will help collapse the left atrial appendage


13


such that spring


90


need not be as large as in FIG.


16


.





FIG. 19

shows an alternative embodiment of the device where the membrane


150


is inserted into the left atrial appendage


13


and fills it securing the membrane


150


therein. The membrane


150


may be delivered in a catheter as a compressed material and expanded in the atrial appendage


13


or be delivered in a liquid form which will fill the atrial appendage and be transformed into a membrane by curing with another chemical delivered by the catheter or with the aid of a UV light supplied through a fiber optic cable in the catheter


21


. By filling the left atrial appendage


13


with a membrane material


150


no blood can enter to pool and become a thrombus


30


and no thrombus


30


can exit to cause heart attacks, strokes and ischemia.





FIGS. 20-22

show another embodiment of the invention using an umbrella principle for securing the membrane


40


against the ostium


20


.

FIG. 17

shows closed umbrella struts


160


entering the ostium


20


of left atrial appendage


13


. The membrane


40


is some distance back from the umbrella struts


160


at the bottom of the range of teeth


195


on pole


170


.

FIG. 21

shows the umbrella struts inside of the left atrial appendage


13


with the struts


160


open. Umbrella opening structure


175


on pole


170


pushes the struts out to the umbrella open position. The umbrella opening structure


175


can be pushed to the open position or have a spring loaded mechanism to push the struts


160


to the open position. The ends of the umbrella struts


160


engage the left atrial appendage wall around the ostium


20


and prevent the umbrella from being withdrawn from the left atrial appendage


13


. The ends of the umbrella struts


160


that engage the atrial appendage wall may be blunted or have bulbs on the tips or have padding so as not to puncture the left atrial appendage


13


.

FIG. 22

shows the membrane


40


drawn up against the ostium


20


by ratcheting the membrane along pole


170


. The pawl mechanism


200


engages teeth


195


on pole


170


and is moved forward to snugly block the ostium


20


with the membrane


40


.





FIG. 23

shows a stent


260


applied to the ostium


20


of left atrial appendage


13


. The stent


260


expands after leaving a delivery catheter such that the wall of the stent secures the stent by pressure to the ostium


20


. Membrane


240


folds or is compressed into the delivery catheter and expands as the stent


260


expands and lodges in the ostium


20


of the left atrial appendage


13


.





FIG. 24

shows the left atrial appendage


13


compressed such that the volume of the atrial appendage is reduced to almost nothing. With the volume reduced the atrial appendage will not have a large volume of blood which can produce a thrombus. In the embodiment shown disk


130


and spring


90


pull the left atrial appendage


13


toward membrane


40


. Although

FIG. 24

shows the use of a disk


130


and spring


90


to act on the left appendage any method to reduce the volume of the atrial appendage as much as possible may be used. In addition to physically reducing the volume a substance


270


may be injected into the appendage to further limit its volume, or to clot the blood already present therein.




As shown in

FIG. 24

the membrane


40


is much larger than the ostium


20


. The over-size membrane


40


may be used in all embodiments to ensure that the ostium


20


is completely blocked.




The devices described above may be percutaneously delivered to the left and right atrial appendages


13


,


23


respectively. The devices may have materials in them which enhance visualization or imaging by ultrasound, x-ray or other means making it easier for the device to be implanted and accurately centered over the ostium


20


of the atrial appendage


13


. This may consist of small beads placed strategically on the membrane, the connecting elements, or on the anchors. Referring to

FIG. 1

catheter


21


is seen entering the heart by way of the aorta


12


to the left ventricle


16


passing through the mitral valve


17


and then entering the left atrial appendage


13


to apply the porous membrane


40


in one of the embodiments as disclosed above. In

FIG. 2

the catheter


21


enters the heart from the femoral vein, passes through the inferior vena cava


18


to the right atrium and then passes through the fossa ovalis


19


or through the septum


29


into the left atrium


11


and then approaches the left atrial appendage


13


to apply the porous membrane


40


thereto.

FIG. 3

shows the catheter


21


being applied to the right atrial appendage


23


. Catheter


21


may enter the heart through the jugular vein


28


or the femoral vein to the inferior vena cava


18


.




It should be understood that the invention may be practiced with numerous means of attaching the membrane


40


to cover the ostium


20


of the atrial appendages


13


and


23


. Any combination of the attachment means with adhesives, prongs, stents, anchors, disks, tethers or springs may be used. The membrane may also be inside of the atrial appendages


13


and


23


, or may penetrate the atrial appendage and provide a means to securely lock the membrane device into place. Other means of providing a membrane for blocking blood flow into and blood clots out of the atrial appendages not listed may also be used. A substance may be injected into the appendage to limit its volume, or to clot the blood already present.




In all of the above embodiments the blood of the appendage may be facilitated to clot in order to form a large, immobile mass. Alternatively, the appendage may be filled with any substance that will occupy volume. Examples are fibrin, prosthetic polymers (PLLA), Silicone, or a balloon that is delivered and remains in place for long periods of time.




All of the above embodiments shown and discussed for the left atrial appendage


13


are also useable on the right atrial appendage


23


. Further the invention may be used to close fistulae or connections elsewhere in the body such as the colon or bronchopulmonary systems. The invention may also be used to seal false aneurysms. When the membrane is placed in a false aneurysm it will strengthen the defect and may help to avoid surgery.




Obviously, many modifications and variations of the present invention are possible in light of the above teachings. It is therefore to be understood that, within the scope of the appended claims, the invention may be practiced otherwise than as specifically described.



Claims
  • 1. A method of preventing atrial appendage thrombus from entering the blood stream comprising:securing a membrane over an ostium of the atrial appendage by extending prongs from adjacent an edge of the membrane into the atrial appendage through the ostium; and piercing the wall of the atrial appendage with the prongs extending into the atrial appendage wall substantially adjacent the ostium to secure the membrane in place; thereby: blocking the atrial appendage ostium with the membrane preventing blood from entering the atrial appendage and forming thrombus therein and preventing thrombus formed therein from leaving.
  • 2. A method of preventing atrial appendage thrombus from entering the blood stream as in claim 1 further comprising:centering the membrane over the ostium by attaching the prongs adjacent the edge of the membrane substantially in a circle such that the prongs will position the membrane over the ostium without leaving gaps between the ostium and the membrane.
  • 3. A method of preventing atrial appendage thrombus from entering the blood stream as in claim 1 further comprising:extending a stent between the membrane and the prongs to engage the ostium of the atrial appendage for securing the membrane to the ostium.
  • 4. A method of preventing atrial appendage thrombus from entering the blood stream as in claim 1 further comprising:securing the membrane over the ostium of the atrial appendage by extending stent legs into the atrial appendage through the ostium of the atrial appendage to hold the membrane snugly against the ostium of the atrial appendage.
  • 5. A method of preventing atrial appendage thrombus from entering the blood stream as in claim 1 further comprising:attaching the membrane to the ostium of the atrial appendage by extending a collapsible stent into the ostium such that the stent expands and engages the circumference of the ostium and attaching a collapsible membrane across the lumen of the stent such that opening the stent stretches the membrane across the lumen of the stent thus blocking the ostium.
  • 6. A method of preventing atrial appendage thrombus from entering the blood stream as in claim 1 further comprising:coating the membrane with an anticoagulant drug to prevent thrombosis.
  • 7. A method of preventing atrial appendage thrombus from entering the blood stream as in claim 1 further comprising:providing a porous membrane for encouraging endothelial cells to grow in the membrane thus providing a cell wall over the membrane to prevent thrombosis.
  • 8. A method of preventing atrial appendage thrombus from entering the blood stream as in claim 1 further comprising:injecting a blood coagulating substance into the atrial appendage to clot the blood therein and prevent it from flowing out of the atrial appendage.
  • 9. A method of preventing atrial appendage thrombus from entering the blood stream as in claim 1 further comprising:injecting an ablative chemical into the atrial appendage to ablate myocardial tissue thus preventing electrical propagation of atrial fibrillation.
  • 10. A method for preventing atrial appendage thrombus from entering the blood stream as in claim 1 further comprising:providing a means for centering the membrane over the ostium of the atrial appendage to provide a good seal.
  • 11. A method of obstructing an opening in the body of a patient, said method comprising:minimally invasively inserting a membrane in the opening by use of a catheter to block the opening; and securing the membrane in place by the membrane lodging against the opening and providing prongs adjacent an edge of the membrane extending substantially outwardly for attaching the membrane to body tissue on the opposite side of the opening substantially adjacent the opening.
  • 12. A method of obstructing an opening in the body of a patient as in claim 11 wherein the securing comprises:securing the membrane over a false aneurysm.
  • 13. A method of obstructing an opening in the body of a patient as in claim 11 wherein the securing comprises:securing the membrane over a fistula.
  • 14. A method of obstructing an opening in the body of a patient as in claim 11 wherein the securing comprises:securing the membrane over an ostium of an atrial appendage.
  • 15. A method of preventing thrombus in the atrial appendage of a patient from entering the blood stream, said method comprising:providing a filter membrane between the atrial appendage and the atrium; securing the filter membrane over an ostium of the atrial appendage by extending engagement members substantially outwardly from adjacent an edge of the filter membrane into the atrial appendage through the ostium of the atrial appendage; and piercing the wall of the atrial appendage with the engagement members extending into the atrial appendage wall substantially adjacent the ostium to secure the filter membrane in place; thereby: filtering blood flow to prevent thrombus from flowing out of the atrial appendage.
  • 16. The method as defined in claim 15, wherein the plurality of engagement members is attached adjacent the edge of the filter membrane in a substantially circular configuration, the method further comprising:centering the filter membrane over the ostium by the engagement members positioning the filter membrane relative to the ostium.
  • 17. The method as defined in claim 15, further comprising:expanding a cylindrical support member to which the filter membrane and the engagement members are attached, to engage the ostium of the atrial appendage for securing the filter membrane across the ostium.
  • 18. The method as defined in claim 15, further comprising:attaching the filter membrane and the engagement members to a portion of a collapsible structure; attaching the filter membrane to the ostium of the atrial appendage by extending the collapsible structure into the ostium and expanding the collapsible structure; such that: the collapsible structure expands and engages the circumference of the ostium; and the filter membrane is stretched across the ostium.
  • 19. The method as defined in claim 15, further comprising:coating the filter membrane with an anticoagulant drug to prevent thrombosis.
  • 20. The method as defined in claim 15, wherein the filter membrane is structured to encourage endothelial cells to grow in the filter membrane thus providing a cell wall over the filter membrane to prevent thrombosis.
  • 21. The method as defined in claim 15, further comprising:providing a means for centering the filter membrane over the ostium of the atrial appendage to provide a good seal.
  • 22. A method of preventing atrial appendage thrombus from entering the blood stream comprising:blocking an atrial appendage ostium with a membrane preventing blood from entering the atrial appendage and forming thrombus therein and preventing thrombus formed therein from leaving; and injecting a blood coagulating substance into the atrial appendage to clot blood therein and prevent blood from flowing out of the atrial appendage.
US Referenced Citations (135)
Number Name Date Kind
178283 French Jun 1876 A
1967318 Monahan Jul 1934 A
3844302 Klein Oct 1974 A
3874388 King et al. Apr 1975 A
4007743 Blake Feb 1977 A
4341218 Ü Jul 1982 A
4585000 Hershenson Apr 1986 A
4603693 Conta et al. Aug 1986 A
4665906 Jervis May 1987 A
4710192 Liotta et al. Dec 1987 A
4917089 Sideris Apr 1990 A
4921484 Hillstead May 1990 A
5037810 Saliba, Jr. Aug 1991 A
5041090 Scheglov et al. Aug 1991 A
5041093 Chu Aug 1991 A
5042707 Taheri Aug 1991 A
5053009 Herzberg Oct 1991 A
5064435 Porter Nov 1991 A
5078736 Behl Jan 1992 A
5108420 Marks Apr 1992 A
5171259 Inoue Dec 1992 A
5176692 Wilk et al. Jan 1993 A
5192301 Kamiya et al. Mar 1993 A
5256146 Ensminger et al. Oct 1993 A
5258042 Mehta Nov 1993 A
5284488 Sideris Feb 1994 A
5306234 Johnson Apr 1994 A
5334217 Das Aug 1994 A
5350399 Erlebacher et al. Sep 1994 A
5353784 Nady-Mohamed Oct 1994 A
5370657 Irie Dec 1994 A
5375612 Cottenceau et al. Dec 1994 A
5417699 Klein et al. May 1995 A
5421832 Lefebvre Jun 1995 A
5425744 Fagan et al. Jun 1995 A
5433727 Sideris Jul 1995 A
5443454 Tanabe et al. Aug 1995 A
5451235 Lock et al. Sep 1995 A
5464408 Duc Nov 1995 A
5469867 Schmitt Nov 1995 A
5490856 Person et al. Feb 1996 A
5522822 Phelps et al. Jun 1996 A
5522836 Palermo Jun 1996 A
5527322 Klein et al. Jun 1996 A
5527338 Purdy Jun 1996 A
5591196 Marin et al. Jan 1997 A
5614204 Cochrum Mar 1997 A
5634936 Linden et al. Jun 1997 A
5634942 Chevillon et al. Jun 1997 A
5637097 Yoon Jun 1997 A
5643292 Hart Jul 1997 A
5649953 Lefebvre Jul 1997 A
5662671 Barbut et al. Sep 1997 A
5669933 Simon et al. Sep 1997 A
5681347 Cathcart et al. Oct 1997 A
5690671 McGurk et al. Nov 1997 A
5693067 Purdy Dec 1997 A
5695525 Mulhauser et al. Dec 1997 A
5702421 Schneidt Dec 1997 A
5709224 Behl et al. Jan 1998 A
5709707 Lock et al. Jan 1998 A
5725552 Kotula et al. Mar 1998 A
5725568 Hastings Mar 1998 A
5733294 Forber et al. Mar 1998 A
5735290 Sterman et al. Apr 1998 A
5749883 Halpern May 1998 A
5749894 Engelson May 1998 A
5766219 Horton Jun 1998 A
5769816 Barbut et al. Jun 1998 A
5776097 Massoud Jul 1998 A
5782860 Epstein et al. Jul 1998 A
5800454 Jacobsen et al. Sep 1998 A
5810874 Lefebvre Sep 1998 A
5823198 Jones et al. Oct 1998 A
5830228 Knapp et al. Nov 1998 A
5836913 Orth et al. Nov 1998 A
5836968 Simon et al. Nov 1998 A
5846260 Maahs Dec 1998 A
5846261 Kotula et al. Dec 1998 A
5849005 Garrison et al. Dec 1998 A
5851232 Lois Dec 1998 A
5855597 Jayaraman Jan 1999 A
5865791 Whayne et al. Feb 1999 A
5865802 Yoon et al. Feb 1999 A
5868708 Hart et al. Feb 1999 A
5876367 Kaganov et al. Mar 1999 A
5882340 Yoon Mar 1999 A
5885258 Sachdeva et al. Mar 1999 A
5895399 Barbut et al. Apr 1999 A
5904703 Gilson May 1999 A
5906207 Shen May 1999 A
5910154 Tsugita et al. Jun 1999 A
5911734 Tsugita et al. Jun 1999 A
5916236 Mujis Van de Moer et al. Jun 1999 A
5928192 Maahs Jul 1999 A
5928260 Chin et al. Jul 1999 A
5935147 Kensey et al. Aug 1999 A
5935148 Villar et al. Aug 1999 A
5941249 Maynard Aug 1999 A
5947997 Pavncik et al. Sep 1999 A
5951589 Epstein et al. Sep 1999 A
5954694 Sunseri Sep 1999 A
5957940 Tanner et al. Sep 1999 A
5976174 Ruiz Nov 1999 A
5980555 Barbut et al. Nov 1999 A
5989281 Barbut et al. Nov 1999 A
5993469 McKenzie et al. Nov 1999 A
5997557 Barbut et al. Dec 1999 A
6007523 Mangosong Dec 1999 A
6007557 Ambrisco et al. Dec 1999 A
6010517 Baccaro Jan 2000 A
6010522 Barbut et al. Jan 2000 A
6024754 Engelson Feb 2000 A
6024755 Addis Feb 2000 A
6024756 Huebsch et al. Feb 2000 A
6027520 Tsugita et al. Feb 2000 A
6033420 Hahnen Mar 2000 A
6036720 Abrams et al. Mar 2000 A
6042598 Tsugita et al. Mar 2000 A
6048331 Tsugita et al. Apr 2000 A
6051014 Jang Apr 2000 A
6051015 Maahs Apr 2000 A
6056720 Morse May 2000 A
6063070 Eder May 2000 A
6068621 Balcetta et al. May 2000 A
6074357 Kaganov et al. Jun 2000 A
6079414 Roth Jun 2000 A
6080182 Shaw et al. Jun 2000 A
6080183 Tsugita et al. Jun 2000 A
6083239 Addis Jul 2000 A
6132438 Fleischman et al. Oct 2000 A
6136016 Barbut et al. Oct 2000 A
6139527 Laufer et al. Oct 2000 A
6152144 Lesh et al. Nov 2000 A
6161543 Cox et al. Dec 2000 A
Foreign Referenced Citations (8)
Number Date Country
WO 9313712 Jul 1993 WO
WO 9728749 Aug 1997 WO
WO 9817187 Apr 1998 WO
WO 9905977 Feb 1999 WO
WO 9907289 Feb 1999 WO
WO 9908607 Feb 1999 WO
WO 9930640 Jun 1999 WO
WO 0027292 May 2000 WO
Non-Patent Literature Citations (8)
Entry
Cragg et al., “Nonsurgical Placement of Arterial Endoprostheses: A New Technique Using Nitinol Wire,” Radiology vol. 147, No. 1, pp. 261-263, Apr. 1983.
Cragg, et al., “A New Percutaneous Vena Cava Filter”, AJR: 141, 601-604, Sep. 1983.
Sugita et al., “Nonsurgical Implantation of a Vascular Ring Prosthesis Using Thermal Shape Memory Ti/Ni Alloy (Nitinol Wire),” Trans. Am. Soc. Artif. Intern. Organs, vol. XXXII, 30-34, 1986.
Ruttenberg, “Nonsurgical Therapy of Cardiac Disorders,” Pediatric Consult, vol. 5, No. 2, pages not numbered, 1986.
Rashkind et al., “Nonsurgical Closure of patent ductus arteriosus: clinical application of the Rashkind PDA Occluder System,” Circulation, vol. 75, No. 3, 583-592, Mar. 1987.
Lock et al., “Transcatheter Umbrella Closure of Congenital Heart Defects,” Circulation, vol. 75, No. 3, 593-599, Mar. 1987.
Wessel, et al. “Outpatient Closure of the patent ductus arteriosus,” Circulation, vol. 77, No. 5, 1068-1071, May 1988.
Lock et al., “Transcatheter Closure of Atrial Septal Defects,” Circulation, vol. 79, No. 5, 1091-1099, May 1989.